| FCGR2A | FCGR3A | ||||||
---|---|---|---|---|---|---|---|---|
 | H/H | H/R | R/R | P-value | F/F | F/V | V/V | P-value |
Number of patients (%) | 114 (22.6%) | 261 (51.8%) | 129 (25.6%) | Â | 241 (48.5%) | 206 (41.4%) | 50 (10.1%) | Â |
Age, median (range) | 61 (27–74) | 62 (24–75) | 62 (30–75) | 0.99* | 62 (24–75) | 61 (29–75) | 61 (35–75) | 0.47* |
Sex, female/male | 49/65 | 102/159 | 57/72 | 0.58†| 93/148 | 94/112 | 20/30 | 0.32†|
Location, colon/rectum | 71/43 | 145/116 | 78/51 | 0.41†| 147/94 | 121/85 | 23/27 | 0.15†|
Metastatic sites, 1/>1 | 32/82 | 63/198 | 39/90 | 0.41†| 62/179 | 51/155 | 20/30 | 0.08†|
KRAS, wt/mutated | 62/38 | 150/82 | 61/49 | 0.26†| 126/87 | 111/67 | 31/15 | 0.54†|
BRAF, wt/mutated | 80/11 | 192/26 | 91/10 | 0.88†| 182/18 | 141/21 | 36/7 | 0.28†|
Treatment, FLOX/FLOX + cetuximab | 33/81 | 90/171 | 49/80 | 0.34†| 79/162 | 75/131 | 15/35 | 0.58†|
Response; response/no-response | 54/60 | 121/140 | 57/72 | 0.89†| 109/132 | 93/113 | 25/25 | 0.82†|
PFS (months), median | 8.3 | 7.9 | 7.6 | 0.45‡ | 7.9 | 7.6 | 8.4 | 0.76‡ |
OS (months), median | 21.9 | 19.8 | 18.2 | 0.42‡ | 19.9 | 20.5 | 19.7 | 0.77‡ |